

DEPARTMENT OF TRADE AND INDUSTRY
DEPARTEMENT VAN HANDEL EN NYWERHEID

REPUBLIC OF SOUTH AFRICA



REPUBLIEK VAN SUID-AFRIKA

LETTERS PATENT
(PATENTS ACT, 1978)

PATENTBRIEF
(WET OP PATENTE, 1978)

94/3464

No.

HUMAN GENOME SCIENCES, INC.

WHEREAS

NADEMAAL

(Hereinafter called "the Patentee")
(Hieronder "die Patenthouer" genoem)

has applied to me for the grant of a patent in respect of an invention described and claimed in the complete specification
aansoek by my gedoen het om die verlening van 'n patent ten opsigte van 'n uitvinding wat beskryf is en waarop aanspraak

deposited at the Patent Office under the above-mentioned number, a copy of which is annexed, together with the relevant
gemaak word in die volledige spesifikasie wat by die Patentkantoor onder bovermelde nommer ingedien is en waarvan 'n

Form P.2;

afskrif aangeheg is tesame met die betrokke Vorm P. 2;

NOW THEREFORE these Letters Patent are to grant to the Patentee a patent, the effect of which shall be to grant to the
SO IS DIT dat hierdie Patentbrief aan die Patenthouer 'n patent verleen wat die uitwerking het dat, behoudens die

Patentee in the Republic, subject to the provisions of the Act, for the duration of the patent, the right to exclude other persons
bepalings van die Wet, aan die Patenthouer vir die duur van die patent in die Republiek die reg verleen word om ander

from making, using, exercising or disposing of the invention, so that he shall have and enjoy the whole profit and advantage
persone uit te sluit van die vervaardiging, aanwending, uitoefening of van die handsetting van die uitvinding, sodat hy al die

accruing by reason of the invention.

wins en voordeel wat uit die uitvinding voortspruit, verkry en geniet.

IN TESTIMONY WHEREOF the seal of the Patent Office has been affixed at Pretoria with effect from the
TER BETUIGING WAARVAN die seël van die Patentkantoor hierop te Pretoria aangebring is met ingang van die

31ST

day of

JANUARY

nineteen hundred and

NINETY SIX

dag van

eenduisend negehoonderd

Registrar of Patents — Registrateur van Patente

(See overleaf
Blaai om



PATENT

1. The patent remains in force only if the required renewal fees are paid annually after the third year of the date of application.
Die patent is geldig slegs indien die vereiste hernuwingsgeide jaarliks, na die derde jaar vanaf die datum van aansoek betaal word.
2. This document is not valid unless sealed with the seal of the Patent Office, PRETORIA.
Hierdie dokument is nie geldig nie tensy geseël met die seël van die Patentkantoor, PRETORIA.

REPUBLIC OF SOUTH AFRICA		REGISTER OF PATENTS		PATENTS ACT, 1978	
OFFICIAL APPLICATION NO.		LODGING DATE: PROVISIONAL		ACCEPTANCE DATE	
21	01 94/3464	22		47	20-11-95
INTERNATIONAL CLASSIFICATION		LODGING DATE: COMPLETE		GRANTED DATE	
51	C07K, C07H, C12N, A61K	23	19 MAY 1994		1996-01-31
FULL NAME(S) OF APPLICANT(S)/PATENTEE(S)					
71	HUMAN GENOME SCIENCES, INC.				
APPLICANTS SUBSTITUTED:				DATE REGISTERED	
71					
ASSIGNEE(S)				DATE REGISTERED	
71					
FULL NAME(S) OF INVENTOR(S)					
72	JING-SHAN HU LIANG CAO CLAIRE M. FRASER				
PRIORITY CLAIMED		COUNTRY		NUMBER	
N.B. Use International Abbreviation for country (See Schedule 4)		33	US	31	08/207,550
				32	8 MARCH 1994
TITLE OF INVENTION					
54	VASCULAR ENDOTHELIAL GROWTH FACTOR 2				
ADDRESS OF APPLICANT(S)/PATENTEE(S)					
9620 MEDICAL CENTER DRIVE, SUITE 300 ROCKVILLE MARYLAND 20850-3358 USA					
ADDRESS FOR SERVICE				A & A REF:	
74	ADAMS & ADAMS, Pretoria			128404	
PATENT OF ADDITION TO NO.		DATE OF ANY CHANGE			
61					
FRESH APPLICATION BASED ON		DATE OF ANY CHANGE			

[illegible]

ADAMS & ADAMS
PATENT ATTORNEYS
PRETORIA

FORM P7

REPUBLIC OF SOUTH AFRICA
Patents Act, 1978

COMPLETE SPECIFICATION

(Section 30 (1) - Regulation 28)

21	01	OFFICIAL APPLICATION NO
----	----	-------------------------

94/3464

22	LODGING DATE
----	--------------

19 MAY 1994

51	INTERNATIONAL CLASSIFICATION
----	------------------------------

C07K, C07H, C12N, A61K

71	FULL NAME(S) OF APPLICANT(S)
----	------------------------------

HUMAN GENOME SCIENCES, INC.

72	FULL NAME(S) OF INVENTOR(S)
----	-----------------------------

JING-SHAN HU
LIANG CAO
CLAIRE M. FRASER

54	TITLE OF INVENTION
----	--------------------

VASCULAR ENDOTHELIAL GROWTH FACTOR 2

Vascular Endothelial Growth Factor 2

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a human vascular endothelial growth factor 2 (VEGF2). The invention also relates to inhibiting the action of such polypeptide.

The formation of new blood vessels, or angiogenesis, is essential for embryonic development, subsequent growth, and tissue repair. Angiogenesis is an essential part of the growth of human solid cancer, and abnormal angiogenesis is associated with other diseases such as rheumatoid arthritis, psoriasis, and diabetic retinopathy (Folkman, J. and Klagsbrun, M., Science 235:442-447, (1987)).

Several factors are involved in angiogenesis. Both acidic and basic fibroblast growth factor molecules that are mitogens for endothelial cells and other cell types. Angiotropin and angiogenin can induce angiogenesis, although their functions are unclear (Folkman, J., 1993, Cancer Medicine pp. 153-170, Lea and Febiger Press). A highly selective mitogen for vascular endothelial cells is vascular endothelial growth factor or VEGF Ferrara, N., et al., Endocr. Rev. 13:19-32, (1992)). Vascular

endothelial growth factor is a secreted angiogenic mitogen whose target cell specificity appears to be restricted to vascular endothelial cells. The murine VEGF gene has been characterized and its expression pattern in embryogenesis has been analyzed. A persistent expression of VEGF was observed in epithelial cells adjacent to fenestrated endothelium, e.g., in choroid plexus and in kidney glomeruli. The data was consistent with a role of VEGF as a multifunctional regulator of endothelial cell growth and differentiation. Breier, G. et al. Development, 114:521-532 (1992).

VEGF can promote angiogenesis. VEGF shares sequence homology with human platelet-derived growth factor, PDGF α and PDGF β (Leung, D.W., et al., Science, 1306-1309, (1989)). The extent of homology is about 21 % and 24 % respectively. Eight cysteine residues are conserved between all three members. Although they are similar, there are specific differences between VEGF and PDGF. While PDGF is a major growth factor for connective tissue, VEGF is highly specific for endothelial cells. VEGF is also known as vascular permeability factor (VPM) and follicle stellate-derived growth factor. It is a heparin-binding dimeric polypeptide.

VEGF has four different forms of 121, 165, 189 and 206 amino acids due to alternative splicing. VEGF121 and VEGF165 are soluble and are capable of promoting angiogenesis, whereas VEGF189 and VEGF206 are bound to heparin containing proteoglycans in the cell surface. The temporal and spatial expression of VEGF has been correlated with physiological proliferation of the blood vessels (Gajdusek, C.M., and Carbon, S.J., Cell Physiol., 139:570-579, (1989)); McNeil, P.L., Muthukrishnan, L., Warder, E., D'Amore, P.A., J. Cell. Biol., 109:811-822, (1989)). Its high affinity binding sites are localized only on endothelial cells in tissue sections (Jakeman, L.B., et al., Clin. Invest. 89:244-253, (1989)). The factor can be isolated from pituitary cells and several tumor cell lines, and has been implicated in some human gliomas (Plate, K.H. Nature 359:845-848, (1992)).

Interestingly, expression of VEGF121 or VEGF165 confers on Chinese hamster ovary cells the ability to form tumors in nude mice (Ferrara, N., et al., J. Clin. Invest. 91:160-170, (1993)). Finally, the inhibition of VEGF function by anti-VEGF monoclonal antibodies was shown to inhibit tumor growth in immune-deficient mice (Kim, K.J., Nature 362:841-844, (1993)).

Vascular permeability factor, also known as VEGF, has also been found to be responsible for persistent microvascular hyperpermeability to plasma proteins even after the cessation of injury, which is a characteristic feature of normal wound healing. This suggests that VPF (or VEGF) is an important factor in wound healing. Brown, L.F. et al., J. Exp. Med., 176:1375-9 (1992).

U.S. Patent No. 5,073,492, issued December 17, 1991 to Chen et al., discloses a method for synergistically enhancing endothelial cell growth in an appropriate environment which comprises adding to the environment, VEGF, effectors and serum-derived factor. Also, vascular endothelial cell growth factor C sub-unit DNA has been prepared by polymerase chain reaction techniques. The DNA encodes a protein that may exist as either a heterodimer or homodimer. The protein is a mammalian vascular endothelial cell mitogen and, as such, is useful for the promotion of vascular development and repair, as disclosed in European Patent Application No. 92302750.2, published September 30, 1992.

In accordance with one aspect of the present invention, there is provided a novel mature polypeptide which is a VEGF2 as well as fragments, analogs and derivatives thereof. The VEGF2 of the present invention is of human origin.

In accordance with another aspect of the present invention, there are provided polynucleotides (DNA or RNA) which encode such polypeptides.

In accordance with still another aspect of the present invention, there is provided a process for producing such polypeptide by recombinant techniques.

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptide, or polynucleotide encoding such polypeptide, for therapeutic purposes, for example, as a wound-healing agent, to promote growth of damaged bone and tissue and promote endothelialization as well as for diagnosis of tumors, cancer therapy and to identify and isolate unknown receptors of VEGF2.

In accordance with yet another aspect of the present invention, there is provided an antibody against the VEGF2 and a process for producing such antibody.

In accordance with yet another aspect of the present invention, there are provided antagonist/inhibitors to VEGF2, which may be used to inhibit the action of such polypeptide, for example, to prevent tumor angiogenesis.

These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.

The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.

Fig. 1 depicts the polynucleotide sequence which encodes for VEGF2, and the corresponding deduced amino acid sequence of the full length VEGF2 polypeptide comprising 350 amino acid residues of which approximately the first 24 amino acids represent the leader sequence. The standard three-letter abbreviation has been used to depict the amino acid sequence.

Fig. 2 shows the homology between growth factor PDGF α , PDGF β , VEGF and VEGF2 at the amino acid level.

Fig. 3 shows, in table-form, the percent homology between PDGF α , PDGF β , VEGF and VEGF2.

Fig. 4 shows the presence of mRNA for VEGF2 in breast tumor cell lines.

Fig. 5 depicts the results of a Northern blot analysis of VEGF2 in human adult tissues.

Fig. 6 shows the results of running VEGF2 and SDS-PAGE gel after in vitro transcription/translation. The full length and partial VEGF2 cDNA were transcribed and translated in a coupled reaction in the presence of ^{35}S -methionine. The translated products were analyzed by 4-20% gradient SDS PAGE and exposed to X-ray film.

In accordance with one aspect of the present invention, there is provided an isolated nucleic acid (polynucleotide) which encodes for the mature polypeptide having the deduced amino acid sequence of Figure 1 or for the mature polypeptide encoded by the cDNA of the clone deposited as ATCC Deposit No. 75698 on 4 March 1994.

A polynucleotide encoding a polypeptide of the present invention may be obtained from early stage human embryo (week 8 to 9) osteoclastomas, adult heart or several breast cancer cell lines. The polynucleotide of this invention was discovered in a cDNA library derived from early stage human embryo week 9. It is structurally related to the VEGF/PDGF family. It contains an open reading frame encoding a protein of about 350 amino acid residues of which approximately the first 24 amino acid residues are likely to be leader sequence such that the mature protein comprises 326 amino acids, and which protein exhibits the highest homology to vascular endothelial growth factor (30% identity), followed by PDGF α (23%) and PDGF β (22%), (see Figure 3). It is particularly important that all eight cysteines are conserved within all four members of the family (see boxed areas of Figure 2). In addition, the signature for the PDGF/VEGF family, PXC VXXXRCXGCCN, is conserved in VEGF2 (see Figure 2). The homology between VEGF2, VEGF and the two PDGFs is at the protein sequence level. No nucleotide sequence homology can be detected, and therefore, it would be difficult to isolate the VEGF2 through simple approaches such as low stringency hybridization.

The polynucleotide of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA,

genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature polypeptide may be identical to the coding sequence shown in Figure 1 or that of the deposited clone or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same, mature polypeptide as the DNA of Figure 1 or the deposited cDNA.

The polynucleotide which encodes for the mature polypeptide of Figure 1 or for the mature polypeptide encoded by the deposited cDNA may include: only the coding sequence for the mature polypeptide; the coding sequence for the mature polypeptide and additional coding sequence such as a leader or secretory sequence or a proprotein sequence; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as introns or non-coding sequence 5' and/or 3' of the coding sequence for the mature polypeptide.

Thus, the term "polynucleotide encoding a polypeptide" encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.

The present invention further relates to variants of the hereinabove described polynucleotides which encode for fragments, analogs and derivatives of the polypeptide having the deduced amino acid sequence of Figure 1 or the polypeptide encoded by the cDNA of the deposited clone. The variant of the polynucleotide may be a naturally occurring allelic variant of the polynucleotide or a non-naturally occurring variant of the polynucleotide.

Thus, the present invention includes polynucleotides encoding the same mature polypeptide as shown in Figure 1 or the same mature polypeptide encoded by the cDNA of the deposited clone as well as variants of such polynucleotides which variants

encode for an fragment, derivative or analog of the polypeptide of Figure 1 or the polypeptide encoded by the cDNA of the deposited clone. Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.

As hereinabove indicated, the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in Figure 1 or of the coding sequence of the deposited clone. As known in the art, an allelic variant is an alternate form of a polynucleotide sequence which have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.

The present invention also includes polynucleotides, wherein the coding sequence for the mature polypeptide may be fused in the same reading frame to a polynucleotide which aids in expression and secretion of a polypeptide from a host cell, for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell. The polypeptide having a leader sequence is a preprotein and may have the leader sequence cleaved by the host cell to form the mature form of the polypeptide. The polynucleotides may also encode for a proprotein which is the mature protein plus additional 5' amino acid residues. A mature protein having a prosequence is a proprotein and is an inactive form of the protein. Once the prosequence is cleaved an active mature protein remains.

Thus, for example, the polynucleotide of the present invention may encode for a mature protein, or for a protein having a prosequence or for a protein having both a prosequence and presequence (leader sequence).

The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptide of the present invention. The marker sequence may be a hexa-histidine tag

supplied by a pQE-9 vector to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).

The present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 50% and preferably 70% identity between the sequences. The present invention particularly relates to polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which retain substantially the same biological function or activity as the mature polypeptide encoded by the cDNA of Figure 1 or the deposited cDNA.

The deposit(s) referred to herein will be maintained under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure. These deposits are provided merely as a convenience and are not an admission that a deposit is required under 35 U.S.C. § 112. The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with the description of sequences herein. A license may be required to make, use or sell the deposited materials, and no such license is hereby granted.

The present invention further relates to a VEGF2 polypeptide which has the deduced amino acid sequence of Figure 1 or which has the amino acid sequence encoded by the deposited

cDNA, as well as fragments, analogs and derivatives of such polypeptide.

The terms "fragment," "derivative" and "analog" when referring to the polypeptide of Figure 1 or that encoded by the deposited cDNA, means a polypeptide which retains essentially the same biological function or activity as such polypeptide. Thus, an analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide.

The polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.

The fragment, derivative or analog of the polypeptide of Figure 1 or that encoded by the deposited cDNA may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not

isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such polynucleotide or polypeptide could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the VEGF2 genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

The polynucleotide of the present invention may be employed for producing a polypeptide by recombinant techniques. Thus, for example, the polynucleotide sequence may be included in any one of a variety of expression vehicles, in particular vectors or plasmids for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other plasmid or vector may be used as long as it is replicable and viable in the host.

As hereinabove described, the appropriate DNA sequence may be inserted into the vector by a variety of procedures. In

general, the DNA sequence is inserted into an appropriate restriction endonuclease sites by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the *E. coli*. lac or trp, the phage lambda P_L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

In addition, the expression vectors preferably contain a gene to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E. coli*.

The vector containing the appropriate DNA sequence as herein above described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, *Salmonella typhimurium* *Streptomyces*; fungal cells, such as yeast; insect cells, such as *Drosophila* and Sf9; animal cells such as CHO, COS or Bowes melanoma; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such

as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example. Bacterial: pQE70, pQE-9 (Qiagen), pBs, phagescript, PsiX174, pBluescript SK, pBsKS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLneo, pSV2cat, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P_R, P_L and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

In a further embodiment, the present invention relates to host cells containing the above-described construct. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, 1986)).

The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the

recombinant sequence. Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook. et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, (Cold Spring Harbor, N.Y., 1989), the disclosure of which is hereby incorporated by reference.

Transcription of a DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin (bp 100 to 270), a cytomegalovirus early promoter enhancer, a polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including

an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a matter of choice.

As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is derepressed by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw

cycling, sonication, mechanical disruption, or use of cell lysing agents.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

VEGF2 is recovered and purified from recombinant cell cultures by methods used heretofore, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography and lectin chromatography. It is preferred to have low concentrations (approximately 0.1-5mM) of calcium ion present during purification (Price, et al., J. Biol. Chem., 244:917 (1969)). Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

The polypeptides of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated with

mammalian or other eukaryotic carbohydrates or may be non-glycosylated.

VEGF2 is useful as a wound healing agent, particularly where it is necessary to re-vascularize damaged tissues, or where new capillary angiogenesis is important. Therefore, it may be used for treatment of full-thickness wounds such as dermal ulcers, including pressure sores, venous ulcers, and diabetic ulcers. In addition, it can be used in the treatment of full-thickness burns and injuries where angiogenesis is desired to prepare the burn in injured sites for a skin graft and flap. In this case, it should be applied directly at the sites. Similar, VEGF2 can be used in plastic surgery when reconstruction is required following a burn, other trauma, or even for cosmetic purposes.

VEGF2 may also be used to induce the growth of damaged bone, periodontium or ligament tissue. It may be used in periodontal disease where VEGF2 is applied in a methylcellulose gel to the roots of the diseased teeth, the treatment could lead to the formation of new bone and cementum with collagen fiber ingrowths. It can be used for regenerating supporting tissues of teeth, including alveolar bone, cementum and periodontal ligament, that have been damaged by disease and trauma.

Since angiogenesis is important in keeping wounds clean and non-infected, VEGF2 may be used in association with surgery and following the repair of cuts. It should be particularly useful in the treatment of abdominal wounds where there is a high risk of infection.

VEGF2 can be used for the promotion of endothelialization in vascular graft surgery. In the case of vascular grafts using either transplanted or synthetic material, VEGF2 can be applied to the surface of the graft or at the junction to promote the growth of the vascular endothelial cells. One derivation of this is that VEGF2 can be used to repair the damage of myocardial infarction and other occasions where coronary bypass surgery is needed by stimulating the growth of

the transplanted tissue. Related to this is the use of VEGF2 to repair the cardiac vascular system after ischemia.

The identification of VEGF2 can be used for the generation of certain inhibitors of vascular endothelial growth factor. Since angiogenesis and neovascularization are essential steps in solid tumor growth, inhibition of angiogenic activity of the vascular endothelial growth factor is very useful to prevent the further growth, retard, or even regress solid tumors. Although the level of expression of VEGF2 is extremely low in normal tissues including breast, it can be found expressed at moderate levels in at least two breast tumor cell lines that are derived from malignant tumors. It is, therefore, possible that VEGF2 is involved in tumor angiogenesis and growth.

VEGF2 can be used for in vitro culturing of vascular endothelial cells, where it can be added to the conditional medium to a concentration from 10 pg/ml to 10 ng/ml.

The polypeptide of the present invention may also be employed in accordance with the present invention by expression of such polypeptide *in vivo*, which is often referred to as "gene therapy."

Thus, for example, cells such as bone marrow cells may be engineered with a polynucleotide (DNA or RNA) encoding for the polypeptide *ex vivo*, the engineered cells are then provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding for the polypeptide of the present invention.

Similarly, cells may be engineered *in vivo* for expression of the polypeptide *in vivo*, for example, by procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells *in vivo* and expression of the polypeptide *in vivo*. These and other methods for administering a

polypeptide of the present invention by such methods should be apparent to those skilled in the art from the teachings of the present invention. For example, the expression vehicle for engineering cells may be other than a retroviral particle, for example, an adenovirus, which may be used to engineer cells *in vivo* after combination with a suitable delivery vehicle.

The polypeptide of the present invention may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the protein, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of administration.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptide of the present invention may be employed in conjunction with other therapeutic compounds.

The pharmaceutical compositions may be administered in a convenient manner, such as the oral, and intravenous routes, and is preferably administered topically. The amounts and dosage regimens of VEGF2 administered to a subject will depend on a number of factors, such as the mode of administration, the nature of the condition being treated, the body weight of the subject being treated and the judgment of the prescribing physician. Generally speaking, it is given, for example, in therapeutically effective doses of at least about 10 $\mu\text{g/kg}$ body weight and, in most cases, it would be administered in an amount not in excess of about 8 mg/kg body weight per day and preferably the dosage is

from about 10 $\mu\text{g/kg}$ body weight to about 1 mg/kg body weight daily, taking into the account the routes of administration, symptoms, etc.

The sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphism's) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the cDNA is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include *in situ* hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be

used with cDNA as short as 500 or 600 bases; however, clones larger than 2,000 bp have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. FISH requires use of the clone from which the EST was derived, and the longer the better. For example, 2,000 bp is good, 4,000 is better, and more than 4,000 is probably not necessary to get good results a reasonable percentage of the time. For a review of this technique, see Verma et al., Human Chromosomes: a Manual of Basic Techniques. Pergamon Press, New York (1988).

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

With current resolution of physical mapping and genetic mapping techniques, a cDNA precisely localized to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes. (This assumes 1 megabase mapping resolution and one gene per 20 kb).

Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that cDNA sequence. Ultimately, complete sequencing of genes from

several individuals is required to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

The present invention is further directed to inhibiting VEGF2 *in vivo* by the use of antisense technology. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the mature polynucleotide sequence, which encodes for the polypeptide of the present invention, is used to design an antisense RNA oligonucleotide of from 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al, Nucl. Acids Res., 6:3073 (1979); Cooney et al, Science, 241:456 (1988); and Dervan et al, Science, 251: 1360 (1991), thereby preventing transcription and the production of VEGF2. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of an mRNA molecule into the VEGF2 (antisense - Okano, J. Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)).

Alternatively, the oligonucleotides described above can be delivered to cells by procedures in the art such that the anti-sense RNA or DNA may be expressed *in vivo* to inhibit production of VEGF2 in the manner described above.

Antisense constructs to VEGF2, therefore, may inhibit the angiogenic activity of the VEGF2 and prevent the further growth or even regress solid tumors, since angiogenesis and neovascularization are essential steps in solid tumor growth. These antisense constructs may also be used to treat rheumatoid arthritis, psoriasis and diabetic retinopathy which are all characterized by abnormal angiogenesis.

The polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. These antibodies can be,

for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.

Antibodies generated against the polypeptide corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptide into an animal or by administering the polypeptide to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies binding the whole native polypeptide. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.

For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, *Nature*, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96).

Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention.

Neutralization antibodies can be identified and applied to mask the vascular endothelial growth factor, and that has been shown in mice model systems against VEGF. VEGF2 can also be inactivated by certain dominant negative mutants within the gene itself. It is known that both PDGF α and β form either heterodimers or homodimers, and VEGF forms homodimers. Similar interaction between VEGF2 could be expected. These antibodies therefore may be used to block the angiogenic activity of VEGF2

and retard the growth of solid tumors. These antibodies may also be used to treat inflammation caused by the increased vascular permeability which results from the presence of VEGF2.

These antibodies may further be used in an immunoassay to detect the presence of tumors in certain individuals. Enzyme immunoassay can be performed from the blood sample of an individual. Elevated levels of VEGF2 can be considered diagnostic of cancer.

The present invention is also directed to antagonist/inhibitors of the polypeptides of the present invention. The antagonist/inhibitors are those which inhibit or eliminate the function of the polypeptide.

Thus, for example, antagonists bind to a polypeptide of the present invention and inhibit or eliminate its function. The antagonist, for example, could be an antibody against the polypeptide which binds to the polypeptide or, in some cases, an oligonucleotide. An example of an inhibitor is a small molecule which binds to and occupies the catalytic site of the polypeptide thereby making the catalytic site inaccessible to substrate such that normal biological activity is prevented. Examples of small molecules include but are not limited to small peptides or peptide-like molecules.

Truncated versions of VEGF2 can also be produced that are capable of interacting with wild type VEGF2 form dimers that fail activate endothelial cell growth, therefore inactivated the endogenous VEGF2. Or, mutant forms of VEGF2 form dimers themselves and occupies the ligand binding domain of the proper tyrosine Kinase receptors on the target cell surface, but fail to activate the cell growth.

Alternatively, antagonists to the polypeptides of the present invention may be employed which bind to the receptors to which a polypeptide of the present invention normally binds. The antagonists may be closely related proteins such that they recognize and bind to the receptor sites of the natural protein, however, they are inactive forms of the natural protein and

thereby prevent the action of VEGF2 since receptor sites are occupied. In these ways, the action of the VEGF2 is prevented and the antagonist/inhibitors may be used therapeutically as an anti-tumor drug by occupying the receptor sites of tumors which are recognized by VEGF2 or by inactivating VEGF2 itself. The antagonist/inhibitors may also be used to prevent inflammation due to the increased vascular permeability action of VEGF2. The antagonist/inhibitors may also be used to treat solid tumor growth, diabetic retinopathy, psoriasis and rheumatoid arthritis.

The antagonist/inhibitors may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as hereinabove described.

The present invention will be further described with reference to the following examples; however, it is to be understood that the present invention is not limited to such examples. All parts or amounts, unless otherwise specified, are by weight.

In order to facilitate understanding of the following examples, certain frequently occurring methods and/or terms will be described.

"Plasmids" are designated by a lower case p preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.

"Digestion" of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan. For analytical purposes, typically 1 μ g of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 μ l of buffer solution. For the purpose of

isolating DNA fragments for plasmid construction, typically 5 to 50 μ g of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion the reaction is electrophoresed directly on a polyacrylamide gel to isolate the desired fragment.

Size separation of the cleaved fragments is performed using 8 percent polyacrylamide gel described by Goeddel, D. et al., Nucleic Acids Res., 8:4057 (1980).

"Oligonucleotides" refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.

"Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T., et al., Id., p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units of T4 DNA ligase ("ligase") per 0.5 μ g of approximately equimolar amounts of the DNA fragments to be ligated.

Unless otherwise stated, transformation was performed as described by the method of Graham, F. and Van der Eb, A., Virology, 52:456-457 (1973).

Example 1

Expression pattern of VEGF2 in human tissues and breast cancer cell lines

Northern blot analysis was carried out to examine the levels of expression of VEGF2 in human tissues and breast cancer cell lines in human tissues. Total cellular RNA samples were

isolated with RNazol™ B system (Biotech Laboratories, Inc.). About 10 µg of total RNA isolated from each breast tissue and cell line specified was separated on 1% agarose gel and blotted onto a nylon filter, (Molecular Cloning, Sambrook Fritsch, and Maniatis, Cold Spring Harbor Press, 1989). The labeling reaction was done according to the Stratagene Prime-It kit with 50 ng DNA fragment. The labeled DNA was purified with a Select-G-50 column from 5' Prime -- 3 Prime, Inc. The filter was then hybridized with radioactive labeled full length VEGF2 gene at 1,000,000 cpm/ml in 0.5 M NaPO₄ and 7 % SDS overnight at 65°C. After wash twice at room temperature and twice at 60°C with 0.5 X SSC, 0.1 % SDS, the filters were then exposed at -70°C overnight with intensifying screen. A message of 1.6 Kd was observed in 2 breast cancer cell lines. Lane #4 represents a very tumorigenic cell line that is estrogen independent for growth. See Figure 4. Also, 10 µg of total RNA from 10 human adult tissues were separated on an agarose gel and blotted onto a nylon filter. The filter was then hybridized with radioactively labeled VEGF2 probe in 7% SDS, 0.5 M NaPO₄, pH 7.2; 1% BSA overnight at 65°C. Following was in 0.2 X SSC at 65°C, the filter was exposed to film for 24 days at -70°C with intensifying screen. See Figure 5.

Example 2

Expression of VEGF2 by in vitro transcription and translation

The VEGF2 cDNA was transcribed and translated in vitro to determine the size of the translatable polypeptide encoded by the full length and partial VEGF2 cDNA. The full length and partial cDNA inserts of VEGF2 in the pBluescript SK vector were amplified by PCR with three pairs of primers, 1) M13-reverse and forward primers; 2) M13-reverse primer and VEGF primer F4; 3) M13-reverse primer and VEGF primer F5. The sequence of these primers are as follows.

M13-2 reverse primer:

5'-ATGCTTCCGGCTCGTATG-3'

This sequence is located upstream of the 5' end of the VEGF2 cDNA insert in the pBluescript vector and is in an anti-sense orientation as the cDNA. A T3 promoter sequence is located between this primer and the VEGF2 cDNA.

M13-2 forward primer:

5'GGGTTTCCAGTCACGAC-3'

This sequence is located downstream of the 3' end of the VEGF2 cDNA insert in the pBluescript vector and is in an anti-sense orientation as the cDNA insert.

VEGF primer F4:

5'-CCACATGGTTCAGGAAAGACA-3'

This sequence is located within the VEGF2 cDNA in an anti-sense orientation from bp 1259-1239, which is about 169 bp away from the 3' end of the stop codon and about 266 bp before the last nucleotide of the cDNA.

PCR reaction with all three pairs of primers produce amplified products with T3 promoter sequence in front of the cDNA insert. The first and third pairs of primers produce PCR products that encode the full polypeptide of VEGF2. The second pair of primers produce PCR product that misses 36 amino acids coding sequence at the C-terminus of the VEGF2 polypeptide.

Approximately 0.5 ug of PCR product from first pair of primers, 1 ug from second pair of primers, 1 ug from third pair of primers were used for in vitro transcription/translation. The in vitro transcription/translation reaction was performed in a 25 ul of volume, using the T_NT™ Coupled Reticulocyte Lysate Systems (promega, CAT# L4950). Specifically, the reaction contains 12.5 ul of T_NT rabbit reticulocyte lysate 2 ul of T_NT reaction buffer, 1 ul of T3 polymerase, 1 ul of 1 mM amino acid mixtrue (minus methionine), 4 ul of ³⁵S-methionine (>1000 Ci/mmol, 10 mCi/ml), 1 ul of 40 U/ul; RNasin ribonuclease inhibitor, 0.5 or 1 ug of PCR products. Nuclease-free H₂O were added to bring the me to 25 ul. The reaction was incubated at 30°C for 2 hours.

Five microliters of the reaction product was analyzed on a 4-20% gradient SDS-PAGE gel. After fixing in 25% isopropanol and 10% acetic acid, the gel was dried and exposed to an X-ray film overnight at 70°C.

As shown in Fig. 6, PCR products containing the full length VEGF2 cDNA and the cDNA missing 266 bp in the 3' untranslated region (3'-UTR) produced the same length of translated products, whose molecular weights are estimated to be 38-40 dk (lanes 1 & 3). The cDNA missing all the 3'UTR and missing sequence encoding the C-terminal 36 amino acids was translated into a polypeptide with an estimated molecular weight of 36-38 kd (lane 2).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: HU, ET AL.
- (ii) TITLE OF INVENTION: Vascular Endothelial Growth Factor 2
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
 - (B) STREET: 6 BECKER FARM ROAD
 - (C) CITY: ROSELAND
 - (D) STATE: NEW JERSEY
 - (E) COUNTRY: USA
 - (F) ZIP: 07068
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: 3.5 INCH DISKETTE
 - (B) COMPUTER: IBM PS/2
 - (C) OPERATING SYSTEM: MS-DOS
 - (D) SOFTWARE: WORD PERFECT 5.1
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/207,550
 - (B) FILING DATE: 8 MARCH 1994
 - (C) CLASSIFICATION:
- (vii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: FERRARO, GREGORY D.
 - (B) REGISTRATION NUMBER: 36,134
 - (C) REFERENCE/DOCKET NUMBER: 325800-99

AAAACCTCACT GTGATCAATA TTTTATATC ATGCAAATA TGTTTAAAT AAAATGAAAA
TTGTATTATA AAAAAAAAAA AAAAA

1500

1525

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 350 AMINO ACIDS

(B) TYPE: AMINO ACID

(C) STRANDEDNESS:

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Thr	Val	Lys	Tyr	Pro	Glu	Tyr	Trp	Lys	Met	Tyr	Lys	Cys	Gln	-20	-15	-10
Leu	Arg	Lys	Gly	Gly	Trp	Gln	His	Asn	Arg	Glu	Gln	Ala	Asn	Leu	-5	1	5
Asn	Ser	Arg	Thr	Glu	Glu	Thr	Ile	Lys	Phe	Ala	Ala	Ala	His	Tyr	10	15	20
Asn	Thr	Glu	Ile	Leu	Lys	Ser	Ile	Asp	Asn	Glu	Trp	Arg	Lys	Thr	25	30	35
Gln	Cys	Met	Pro	Arg	Glu	Val	Cys	Ile	Asp	Val	Gly	Lys	Glu	Phe	40	45	50
Gly	Val	Ala	Thr	Asn	Thr	Phe	Phe	Lys	Pro	Pro	Cys	Val	Ser	Val	55	60	65
Tyr	Arg	Cys	Gly	Gly	Cys	Cys	Asn	Ser	Glu	Gly	Leu	Gln	Cys	Met	70	75	80
Asn	Thr	Ser	Thr	Ser	Tyr	Leu	Ser	Lys	Thr	Leu	Phe	Glu	Ile	Thr	85	90	95
Val	Pro	Leu	Ser	Gln	Gly	Pro	Lys	Pro	Val	Thr	Ile	Ser	Phe	Ala	100	105	110
Asn	His	Thr	Ser	Cys	Arg	Cys	Met	Ser	Lys	Leu	Asp	Val	Tyr	Arg	115	120	125
Gln	Val	His	Ser	Ile	Ile	Arg	Arg	Ser	Leu	Pro	Ala	Thr	Leu	Pro	130	135	140

AAAAC TCACT GTGATCAATA TTTTATATC ATGCAAAATA TGTTTAAAT AAAATGAAAA
 TTGTATTATA AAAAAAAAAA AAAAA

1500

1525

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 350 AMINO ACIDS

(B) TYPE: AMINO ACID

(C) STRANDEDNESS:

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Thr	Val	Lys	Tyr	Pro	Glu	Tyr	Trp	Lys	Met	Tyr	Lys	Cys	Gln	-20	-15	-10
Leu	Arg	Lys	Gly	Gly	Trp	Gln	His	Asn	Arg	Glu	Gln	Ala	Asn	Leu	-5	1	5
Asn	Ser	Arg	Thr	Glu	Glu	Thr	Ile	Lys	Phe	Ala	Ala	Ala	His	Tyr	10	15	20
Asn	Thr	Glu	Ile	Leu	Lys	Ser	Ile	Asp	Asn	Glu	Trp	Arg	Lys	Thr	25	30	35
Gln	Cys	Met	Pro	Arg	Glu	Val	Cys	Ile	Asp	Val	Gly	Lys	Glu	Phe	40	45	50
Gly	Val	Ala	Thr	Asn	Thr	Phe	Phe	Lys	Pro	Pro	Cys	Val	Ser	Val	55	60	65
Tyr	Arg	Cys	Gly	Gly	Cys	Cys	Asn	Ser	Glu	Gly	Leu	Gln	Cys	Met	70	75	80
Asn	Thr	Ser	Thr	Ser	Tyr	Leu	Ser	Lys	Thr	Leu	Phe	Glu	Ile	Thr	85	90	95
Val	Pro	Leu	Ser	Gln	Gly	Pro	Lys	Pro	Val	Thr	Ile	Ser	Phe	Ala	100	105	110
Asn	His	Thr	Ser	Cys	Arg	Cys	Met	Ser	Lys	Leu	Asp	Val	Tyr	Arg	115	120	125
Gln	Val	His	Ser	Ile	Ile	Arg	Arg	Ser	Leu	Pro	Ala	Thr	Leu	Pro	130	135	140

28d

Gln Cys Gln Ala Ala Asn Lys Thr Cys Pro Thr Asn Tyr Met Trp	145	150	155
Asn Asn His Ile Cys Arg Cys Leu Ala Gln Glu Asp Phe Met Phe	160	165	170
Ser Ser Asp Ala Gly Asp Asp Ser Thr Asp Gly Phe His Asp Ile	175	180	185
Cys Gly Pro Asn Lys Glu Leu Asp Glu Glu Thr Cys Gln Cys Val	190	195	200
Cys Arg Ala Gly Leu Arg Pro Ala Ser Cys Gly Pro His Lys Glu	205	210	215
Leu Asp Arg Asn Ser Cys Gln Cys Val Cys Lys Asn Lys Leu Phe	220	225	230
Pro Ser Gln Cys Gly Ala Asn Arg Glu Phe Asp Glu Asn Thr Cys	235	240	245
Gln Cys Val Cys Lys Arg Thr Cys Pro Arg Asn Gln Pro Leu Asn	250	255	260
Pro Gly Lys Cys Ala Cys Glu Cys Thr Glu Ser Pro Gln Lys Cys	265	270	275
Cys Leu Leu Lys Gly Lys Lys Phe His His Gln Thr Cys Ser Cys	280	285	290
Tyr Arg Arg Pro Cys Thr Asn Arg Gln Lys Ala Cys Glu Pro Gly	295	300	305
Phe Ser Tyr Ser Glu Glu Val Cys Arg Cys Val Pro Ser Tyr Trp	310	315	320
Gln Arg Pro Gln Met Ser	325		

CLAIMS

-29-

~~WHAT IS CLAIMED IS:~~

1. An isolated polynucleotide encoding for VEGF2, said polynucleotide selected from the group consisting of
 - (a) a polynucleotide encoding for the VEGF2 polypeptide having the deduced amino acid sequence of Figure 1 or an active fragment, analogue or derivative of said polypeptide;
 - (b) a polynucleotide encoding for the VEGF2 polypeptide having the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 75698 or an active fragment analogue or derivative of said polypeptide.
2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA.
3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA.
4. The polynucleotide of Claim 1 wherein the polynucleotide is genomic DNA.
5. The polynucleotide of Claim 2 wherein said polynucleotide encodes for VEGF2 having the deduced amino acid sequence of Figure 1.
6. The polynucleotide of Claim 2 wherein said polynucleotide encodes for the VEGF2 polypeptide encoded by the cDNA of ATCC Deposit No. 75698.
7. The polynucleotide of Claim 1 having the coding sequence for VEGF2 as shown in Figure 1.
8. The polynucleotide of Claim 2 having the coding sequence for VEGF2 deposited as ATCC Deposit No. 75698.
9. A vector containing the DNA of Claim 2.
10. A host cell genetically engineered with the vector of Claim 9.
11. A process for producing a polypeptide comprising: expressing from the host cell of Claim 10 the polypeptide encoded by said DNA.
12. A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of Claim 9.

An isolated DNA hybridizable to the DNA of Claim 2 and encoding a polypeptide having VEGF2 activity.

14. A polypeptide selected from the group consisting of (i) a VEGF2 polypeptide having the deduced amino acid sequence of Figure 1 and active fragments, analogs and derivatives thereof and (ii) a VEGF2 polypeptide encoded by the cDNA of ATCC Deposit No. 75698 and active fragments, analogs and derivatives of said polypeptide.

15. The polypeptide of Claim 14 wherein the polypeptide is VEGF2 having the deduced amino acid sequence of Figure 1.

16. An antibody against the polypeptide of claim 14.

17. An antagonist against the polypeptide of claim 14.

18. A substance or composition for use in a method for the treatment of a patient having need of VEGF2, said substance or composition comprising a polypeptide of claim 14, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.

19. A substance or composition for use in a method for the treatment of a patient having need to inhibit VEGF2, said substance or composition comprising an antagonist against the polypeptide of Claim 14, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.

20. A pharmaceutical composition comprising the polypeptide of Claim 14 and a pharmaceutically acceptable carrier.

21. A substance or composition for use in a method of treatment as claimed in Claim 18 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide.

22. A new polynucleotide, substantially as herein described.
23. A new vector or host cell, substantially as herein described.
24. A new process for producing a polypeptide, substantially as herein described.
25. A new process for producing cells, substantially as herein described.
26. A new DNA, polypeptide, antibody, or antagonist against a polypeptide, substantially as herein described.
27. A substance or composition for a new use in a method of treatment, substantially as herein described.
28. A new pharmaceutical composition, substantially as herein described.

DATED THIS 19th DAY OF May 1994

C. SLABBERT

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

Q C G A N R E F D E N T C Q C V C K R T
901 CTGCCCCAGAAATCAACCCCTAAATCCTGGAAAATGTGCCTGTGAATGTACAGAAAGTCC
C P R N Q P L N P G K C A C E C T E S P
961 ACAGAAATGCTTGTATAAAGGAAAGAAGTTCCACCACCAAACATGCAGCTGTTACAGACG
Q K C L L K G K K F H H Q T C S C Y R R
1021 GCCATGTACGAACCGCCAGAAGGCTTGTGAGCCAGGATTTTCATATAGTGAAGAAGTGTG
P C T N R Q K A C E P G F S Y S E E V C
1081 TCGTTGTGTCCCTTCATATTGGCAAAGACCACAAATGAGCTAAGATTGTACTGTTTCCA
R C V P S Y W Q R P Q M S
1141 GTTCATCGATTTTCTATTATGAAAACTGTGTTGCCACAGTAGAACTGTCTGTGAACAGA
GAGACCCCTTGTGGGTCCATGCTAACAAAGACAAAAGTCTGTCTTTCCTGAACCATGTGGA
1261 TAACTTTACAGAAATGGACTGGAGCTCATCTGCAAAGGCCTCTTGTAAGACTGGTTTT
CTGCCAATGACCAAACAGCCAAGATTTTCCTCTTGTGATTTCTTTAAAGAATGACTATA
1381 TAATTTATTTCCACTAAAAATATGTTTCTGCATTTCATTTTATAGCAACAACAATTGGT
AAAAC TCACTGTGATCAATATTTTATATCATGCAAAATATGTTTAAATAAAAATGAAAA
1501 TTGTATTATAAAAAAAAAAAAAAAAAA

FIGURE 1

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

1 CGAGGCCACGGCTTATGCAAGCAAAGATCTGGAGGAGCAGTTACGGTCTGKTTCCAGTGT

71 AGATGAACTCATGACTGTACTCTACCCAGAATATTGGAAAATGTACAAGTGTACAGCTAAG

M T V L Y P E Y W K M Y K C Q L R

121 GAAAGGAGGCTGGCAACATAACAGAGAACAGGCCAACCTCAACTCAAGGACAGAAGAGAC

K G G W Q H N R F Q A N L N S R T E E T

181 TATAAAATTTGCTGCAGCACATTATAATACAGAGATCTTGAAGTATTGATAATGAGTG

I K F A A A H Y N T E I L K S I D N E W

241 GAGAAAGACTCAATGCATGCCACGGGAGGTGTGTATAGATGTGGGAAGGAGTTTCGAGT

R K T Q C M P R E V C I D V G K E F G V

301 CGCGACAAACACCTTCTTTAAACCTCCATGTGTGTCCGTCTACAGATGTGGGGGTTCGTG

A T N T F F K P P C V S V Y R C G G C C

361 CAATAGTGAGGGGCTGCAGTGCATGAACACCAGCAGAGCTACCTCAGCAAGACGTTATT

N S E G L Q C M N T S T S Y L S K T L P

421 TGAAATTACAGTGCCTCTCTCTCAAGGCCCAAACAGTAACAATCAGTTTTCGCAATCA

E I T V P L S Q G P K P V T I S F A N H

481 CACTTCCTGCGGATGCATGTCTAACTGGATGTTTACAGACAAGTTCATTCCATTATTAG

T S C R C M S K L D V Y R Q V H S I I R

541 ACGTTCCTGCGCAGCAACACTACCACAGTGTACGGCAGCGAACAAGACCTGCCCCACCAA

R S L P A T L P Q C Q A A N K T C P T N

601 TTACATGTGGAATAATCACATCTGCAGATGCCTGGCTCAGGAAGATTTTATGTTTTCTCTC

Y M W N N H I C R C L A Q E D F M F S S

661 GGATGCTGGAGATGACTCAACAGATGGATTCCATGACATCTGTGGACCAAAACAAGGAGCT

D A G D D S T D G F H D I C G P N K E L

721 GGATGAAGAGACCTGTCTAGTGTGTCTGCAGAGCGGGGCTTCGGCCTGCCACCTGTGGACC

D E E T C Q C V C R A G L R P A S C G P

781 CCACAAAGAACTAGACAGAAACTCATGCCAGTGTGTCTGTAAAAACAACTCTTCCCAAG

H K E L D R N S C Q C V C K N K L F P S

841 CCAATGTGGGGCCAAACGAGAATTTGATGAAAACACATGCCAGTGTGTATGTAAAAGAAC

CORRECTIONS AS FILED.
DATED THIS 12 DAY OF JULY 1994.

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

C. SLABBERT
ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

225,830-147 sheet 1 of 2

	1		50
Pdgfa	.MRTLACLLL	LGGCYLAHVL	AEEAEIPREV IERLARSQIH SIRDLOQLLE
Pdgfb	MNRCWA.LFL	SLCCYLRLVS	AEGDPIPEEL YEMLSDHSIR SFDDLQRLLE
VegfMNFL	SWVEWSLALL	LY..... .LHHAKWSQA
Vegf2MTV	LYPEYWKYK	CQ..... .LRKGGWQH
	51		100
Pdgfa	IDSVGSEDSL	DTSLRAHVE	ATKHVPEKRP LPFRRKRSI.EEAVP
Pdgfb	GDP.GEEDGA	ELDLNMTSRH	SGGELES... .LARGRRSLG SLTIAEPAMI
Vegf	APMAE.....GGGQ	NHHEVVKFMD .VYQR.....
Vegf2	REQANLNSRT	EETIKFAAAH	YNTEILKSID NEWRK.....
	101		150
Pdgfa	AVCKTRTVIY	EIPRSQVDPT	SANFLIWPPC VEVKRCCTGCC NTSSVKQPS
Pdgfb	AECKTRTEVF	EISRLIDRT	NANFLVWPPC VEVQRCGSCC NNRNVOCKPT
Vegf	SYCHPIETLV	DIFQETPDEI	..EYIFKPSV VPLMRCGGCC NDEGLECVPT
Vegf2	TQCMPEVCI	DVGKEPGVAT	..NTFFKPPC VSVYRCGGCC NSEGLQCMNT
	151		200
Pdgfa	RVHRSVKVA	KVEYVRKKPK	LKEVQVRLEE HLEAC.... AT.....
Pdgfb	QVQLRPVQVR	KIEIVRKKPI	PKKATVTLED HLAAC.... ETVAAARPVT
Vegf	EESNITMQIM	RIK.PH..QG	QHIGEMSFLQ HNKCECRPKK DRARQEKSV
Vegf2	STSYLSKTLF	EIT.VPLSQG	PKPVTISFAN HTSCRM SKL DVYRQVHSII
	201		250
PdgfaTSLNPD	YREEDTDVR.
Pdgfb	RSPGGSQEQR	AKTPQTRVTI	RTVRVRRPPK GKRRKFKHTE DKTALKETLG
Vegf	RGK.....	.GKGQKRRK	KSRYKWSVY VGARCCCLMPW SLPGPHF...
Vegf2	RRLPATLPQ	CQAANKTCPT	NYMWNHICR CLAQEDFMFS SDAGDDSTDG
	251		300
Pdgfa
Pdgfb	A.....
VegfCGP...CSE	RRKHLFVQDP QTCKCSCKNT
Vegf2	PHDICGPNKE	LDEETCQCVC	RAGLRPASCG PHKEL...DR NSCQCVCCKN
	301		350
Pdgfa
Pdgfb
Vegf	..DSRCKARQ	LELNERTCRC	DKPRR.....
Vegf2	LPFSQCGANR	.EPDENTCQC	VCKRTCPRNQ PLNPGKACE CTESPQKCLL
	351		398
Pdgfa
Pdgfb
Vegf
Vegf2	KGKKFHHQTC	SCYRRPCTNR	QKACEPGFSY SEEVCRCVPS YWQRPQMS

FIGURE 2

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

HUMAN GENOME SCIENCES, INC.

Percentage (%) of amino acid identities between each pair of genes is shown in the following table.

	PDGF α	PDGF β	VEGF	VEGF2
PDGF α				
PDGF β	48.0			
VEGF	20.7	22.7		
VEGF2	23.5	22.4	30.0	


FIGURE 3

C

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

Expression of VEGF2 in human breast tumor cell lines

1 2 3 4 5 6 7 8 9



28S


18S

- 1. Normal breast
- 2. Breast cancer
- 3-9. Breast cancer cell lines

FIGURE 4

C. STAFF

ADAMS & ADAMS
APPLICANTS/PATENT ATTORNEYS




Expression of VEGF2 mRNA in human adult tissues.

FIGURE 5

C. SLABBERT

ADAMS & ADAMS
APPLICANTS' PATENT ATTORNEYS



Lane 1: 14-C and rainbow M.W. marker
 Lane 2: FGF control
 Lane 3: VEGF2 (M13-reverse & forward primers)
 Lane 4: VEGF2 (M13-reverse & VEGF-F4 primers)
 Lane 5: VEGF2 (M13-reverse & VEGF-F5 primers)

FIGURE 6

C. SLABBERT

ADAMS & ADAMS
 APPLICANTS PATENT ATTORNEYS

1 / 9

FIG. 1A

```

1  CGAGGCCACGGCTTATGCAAGCAAGATCTGGAGGAGCAGTTACGGTCTGTGTCCAGTGT
   -----+-----+-----+-----+-----+-----+-----+
71  AGATGAACCTCATGACTGTACTCTACCCAGAAATATGGAAAAATGTACAAGTGTTCAGCTAAG
   -----+-----+-----+-----+-----+-----+-----+
      M T V L Y P E Y W K M Y K C Q L R
   -----+-----+-----+-----+-----+-----+-----+
121 GAAAGGAGGCTGGCAACATAACAGAGAACAGGCCAACCTCAACTCAAGGACAGAGAGAC
   -----+-----+-----+-----+-----+-----+-----+
      K G G W Q H N R E Q A N L N S R T E E T
   -----+-----+-----+-----+-----+-----+-----+
181 TATAAAATTGCTGCAGCACATTATAACAGAGATCTTGAAAAAGTATTGATAATGAGTG
   -----+-----+-----+-----+-----+-----+-----+
      I K F A A A H Y N T E I L K S I D N E W
   -----+-----+-----+-----+-----+-----+-----+
241 GAGAAAGACTCAATGCATGCCACGGGAGGTGTGTATAGATGTGGGGAAGGAGTTTGGAGT
   -----+-----+-----+-----+-----+-----+-----+
      R K T Q C M P R E V C I D V G K E F G V
   -----+-----+-----+-----+-----+-----+-----+
301 CGCGACAAACACCTTCTTTAAACCTCCATGTGTGTCCGTCTACAGATGTGGGGGTGCTG
   -----+-----+-----+-----+-----+-----+-----+
      A T N T F F K P P C V S V Y R C G G C C
   -----+-----+-----+-----+-----+-----+-----+
361 CAATAGTGAGGGGCTGCAGTGCATGAACACCCAGCAGGCTACCTCAGCAAGACGTTATT
   -----+-----+-----+-----+-----+-----+-----+
      N S E G L Q C M N T S T S Y L S K T L F
   -----+-----+-----+-----+-----+-----+-----+
421 TGAAATTACAGTGCCCTCTCTCAAGGCCCAACCAGTAACAATCAGTTTGGCCAATCA
   -----+-----+-----+-----+-----+-----+-----+

```

MATCH WITH FIG. 1B

D.L. ERLANK

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS.

2 / 9

FIG. 1B

MATCH WITH FIG. 1A

481 E I T V P L S Q G P K P V T I S F A N H
CACTTCCTGCCGATGTCCTAAACTGGATGTTACAGACAAGTTCATTCCATTATTAG
T S C R C M S K L D V Y R Q V H S I I R
541 ACGTTCCTGCCAGCAACACTACCACAGTGTCCAGGCAGCGAACAAGACCTGCCCCCAACAA
R S L P A T L P Q C Q A A N K T C P T N
601 TTACATGTGGAATAATCACATCTGCAGATGCCCTGGCTCAGGAAGATTTTATGTTTCCTC
Y M W N N H I C R C L A Q E D F M F S S
661 GGATGCTGGAGATGACTCAACAGATGGATTCCATGACATCTGTGGACCAACAAGAGCT
D A G D D S T D G F H D I C G P N K E L
721 GGATGAAGAGACCTGTCAGTGTCTGCAGAGCGGGGCTTCGGCCCTGCCAGCTGTGGACC
D E E T C Q C V C R A G L R P A S C G P
781 CCACAAAGAACTAGACAGAACTCATGCCAGTGTCTGTGTAAACAACTCTTCCCCAG
H K E L D R N S C C Q C V C K N K L F P S
841 CCAATGTGGGCCCAACCGAGAATTGTGATGAACAAACACATGCCAGTGTGTATGTAAAGAAC

MATCH WITH FIG. 1C

G. L. ERLANK

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

3 / 9

MATCH WITH FIG. 1B FIG. 1C

901 Q C G A N R E F D E N T C Q C V C K R T
CTGCCCCAGAAATCAACCCCTAAATCCTGGAAAATGTGCCCTGTGAATGTACAGAAAGTCC
C P R N Q P L N P G K C A C E C T E S P
961 ACAGAAATGCTTGTAAAGGAAAGAGTTCACCCACCAACATGCAGCTGTACAGACG
Q K C L L K G K K F H H Q T C S C Y R R
1021 GCCATGTACGAACCGCCAGAGGCTTGTGAGCCAGGATTTTCATATAGTGAAGAAGTGTG
P C T N R Q K A C E P G F S Y S E E V C
1081 TCGTGTGTCCCTTCATATTTGGCAAAGACCACAAATGAGCTAAGATTGTACTGTTTCCA
R C V P S Y W Q R P Q M S
1141 GTTCATCGATTTTCTATTATGGAAAACCTGTGTGCCCACAGTAGAACTGTCTGTGAACAGA
1201 GAGACCCCTGTGGGTCCATGCTAACAAAGACAAAGTCTGTCTTTCCCTGAACCATGTGGA

MATCH WITH FIG. 1D

C. L. ERLANK

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

MATCH WITH FIG. 1C

FIG. 1D

[illegible]

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

5 / 9

FIG. 2A

50

1

pdgfa .MRTLACLLL LGCGYLAHVL AEEAEIPREV IERLARSQIH SIRDLORLLE
 pdgfb MNRCAWA.LFL SLCCYLRLVS AEGDPIPEEL YEMLSDHSIR SFDDLQRLH
 VegfMNFL SWVHWSLALL LY.....
 Vegf2MTV LYPEYWKMYK CQ.....

100

51

pdgfa IDSVGSEDSL DTSLEAHGVH ATKHVPEKRP LPIRRKRSI.EEAVP
 pdgfb GDP.GEEDGA ELDLNMTRSH SGGELES... .LARGRRSLG SLTIAEPAMI
 Vegf APMAE.....GGGQ NHHEVVKFMD .VYQR.....
 Vegf2 REQANLNSRT EETIKFAAAH YNTEILKSID NEWRK.....

150

101

pdgfa AVCKTRTVIY EIPRSQVDPT SANFLIWPCC VEVKRC TGCC NTSSVRCQPS
 pdgfb AECKTRTEVF EISRRLLDRT NANFLVWPPC VEVQRC SGCC NNRNVQCRPT
 Vegf SYCHPIETLV DIFQEYPDEI ..EYIFKPS VPLMRCGGCC NDEGLECVPT
 Vegf2 TQCMPREVCI DVGKEFGVAT ..NTFFKPPC VSVYRCGGCC NSEGLQCMNT

200

151

pdgfa RVHRSVKVA KVEYVRKKPK LKEVQVRLEE HLECAC..... AT.....
 pdgfb QVQLRPVQVR KIETVRKKPI FKATVTLED HLACKC..... ETVAARPV
 Vegf EESNITMQIM RIK.PH..QG QHIGEMSFLO HNRCECRPKK DRARQEKKS
 Vegf2 STSYLSKTLF EIT.VPLSQG PKPVTISFAN HTSCRCRMSKL DVYRQVHSII

MATCH WITH FIG. 2B

6 / 9

FIG. 2B

MATCH WITH FIG. 2A

	250
PdgfaTSLNPD YREEDTDVR.
Pdgfb	RSPGGSQEQR AKTPQTRVTI RTVRVRRPPK GKHRKFKHTH DKTALKETLG
Vegf	RGK.....GKGQKRKRK KSRYKSWSVY VGARCCCLMPW SLPGPHP...
Vegf2	RRSLPATLPQ CQAANKTCPT NYMWNHICR CLAQEDFMFS SDAGDDSDTDG
	251
Pdgfa
Pdgfb	A.....
VegfCGP....CSE RRKHLFVQDP QTCKCCKNT
Vegf2	FHDICGPNKE LDEETCQCVC RAGLRPASC GPHKEL...DR NSCQCVCCKNK
	300
	301
Pdgfa
Pdgfb
Vegf	..DSRCKARQ LELNERTCRC DKPRR.....
Vegf2	LFPSQCGANR .EFDENTCQC VCKRTCPRNQ PLNPGKCACE CTESPOKCLL
	350
	351
Pdgfa
Pdgfb
Vegf
Vegf2	KGKFFHHQTC SCYRRPCTNR QKACEPGFSY SEEVCRVPS YWQRPQMS
	398

G. L. ERLANK

 ADAMS & ADAMS
 APPLICANTS PATENT ATTORNEYS

7 / 9

FIG. 3


PERCENTAGE (%) OF AMINO ACID IDENTITIES
BETWEEN EACH PAIR OF GENES IS SHOWN IN THE
FLOWING TABLE.

	PDGF α	PDGF β	VEGF	VEGF2
PDGF α				
PDGF β	48.0			
VEGF	20.7	22.7		
VEGF2	23.5	22.4	30.0	

FIG. 4

EXPRESSION OF VEGF2 IN
IN HUMAN BREAST TUMOR CELL LINES

1 2 3 4 5 6 7 8 9



1. NORMAL BREAST


2. BREAST CANCER

3-9. BREAST CANCER CELL LINES

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

8 / 9

FIG. 5




Expression of VEGF2 mRNA in human adult tissues.

G.L. ERLANK

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS

9 / 9

FIG. 6



Lane 1: 14-C and rainbow M.W. marker
Lane 2: FGF control
Lane 3: VEGF2 (M13-reverse & forward primers)
Lane 4: VEGF2 (M13-reverse & VEGF-F4 primers)
Lane 5: VEGF2 (M13-reverse & VEGF-F5 primers)

G. L. ERLANK

ADAMS & ADAMS
APPLICANTS PATENT ATTORNEYS